Evidence map›Paper›PMID 33419871›Full record

SynthesisRMD open2021

Pharmacological and non-pharmacological therapeutic strategies in difficult-to-treat rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of difficult-to-treat rheumatoid arthritis.

Nadia M T Roodenrijs, Attila Hamar, Melinda Kedves, György Nagy, Jacob M van Laar, Désirée van der Heijde, Paco M J Welsing

Open access · goldAbstract readSystematic Review
In one paragraph

Synthesis in RMD open, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed, 6 pooled it
13.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 6 syntheses or guidelines pooled it, 103 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Guideline
  6. Pooled it
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Observational
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 3 countries.

Nadia M T RoodenrijsRheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands n.m.t.roodenrijs@umcutrecht.nl.ORCID 0000-0002-4364-3183
Attila HamarRheumatology, University of Debrecen, Debrecen, Hungary.
Melinda KedvesRheumatology, Bacs-Kiskun Megyei Korhaz, Kecskemet, Hungary.
György NagyGenetics, Cell- and Immunobiology & Rheumatology & Clinical Rheumatology, Semmelweis University, Budapest, Hungary.
Jacob M van LaarRheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands.
Désirée van der HeijdeRheumatology, Leiden University Medical Center, Leiden, The Netherlands.ORCID 0000-0002-5781-158X
Paco M J WelsingRheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands.
University Medical Center Utrecht · NLBács-Kiskun Megyei Kórház · HULeiden University Medical Center · NLSemmelweis University · HUUniversity of Debrecen · HU

Funding

TRAINING PROGRAM IN COMPLEMENTARY &ALTERNATIVE MEDICINET32AT000052 · NCCIH · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI TAYLOR, ANN GILL · 2000 to 2010
$3.6M
GLUCOSAMINE IN CARTILAGE HOMEOSTASIS AND DEGRADATIONK08AT000052 · NCCIH · SCRIPPS RESEARCH INSTITUTE · PI SHIKHMAN, ALEXANDER R · 2000 to 2004
$459k
NCCIH NIH HHS F32 AT000052NCCIH NIH HHS K08 AT000052NCCIH NIH HHS T32 AT000052
6 · The paper itself

Abstract

objectivesTo summarise, by a systematic literature review (SLR), the evidence regarding pharmacological and non-pharmacological therapeutic strategies in difficult-to-treat rheumatoid arthritis (D2T RA), informing the EULAR recommendations for the management of D2T RA.

methodsPubMed, Embase and Cochrane databases were searched up to December 2019. Relevant papers were selected and appraised.

resultsTwo hundred seven (207) papers studied therapeutic strategies. Limited evidence was found on effective and safe disease-modifying antirheumatic drugs (DMARDs) in patients with comorbidities and other contraindications that limit DMARD options (patients with obesity, hepatitis B and C, risk of venous thromboembolisms, pregnancy and lactation). In patients who previously failed biological (b-)DMARDs, all currently used b/targeted synthetic (ts-)DMARDs were found to be more effective than placebo. In patients who previously failed a tumour necrosis factor inhibitor (TNFi), there was a tendency of non-TNFi bDMARDs to be more effective than TNFis. Generally, effectiveness decreased in patients who previously failed a higher number of bDMARDs. Additionally, exercise, psychological, educational and self-management interventions were found to improve non-inflammatory complaints (mainly functional disability, pain, fatigue), education to improve goal setting, and self-management programmes, educational and psychological interventions to improve self-management.The identified evidence had several limitations: (1) no studies were found in patients with D2T RA specifically, (2) heterogeneous outcome criteria were used and (3) most studies had a moderate or high risk of bias.

conclusionsThis SLR underscores the scarcity of high-quality evidence on the pharmacological and non-pharmacological treatment of patients with D2T RA. Effectiveness of b/tsDMARDs decreased in RA patients who had failed a higher number of bDMARDs and a subsequent b/tsDMARD of a previously not targeted mechanism of action was somewhat more effective. Additionally, a beneficial effect of non-pharmacological interventions was found for improvement of non-inflammatory complaints, goal setting and self-management.

Indexed as

Antirheumatic AgentsArthritis, RheumatoidBiological ProductsDrug Therapy, CombinationFemaleHumansTumor Necrosis Factor-alphaAntirheumatic AgentsBiological ProductsTumor Necrosis Factor-alphaarthritisbiological therapyoccupational therapypatient reported outcome measuresrheumatoidtherapeutics

Identifiers

PMID33419871
PMCPMC7798678
OpenAlexW3118696437

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.